Use of a Highly-sensitive Cardiac Troponin I Assay in a Screening Population for Hypertrophic Cardiomyopathy: a Case-referent Study

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2013 Sep 12

PMID 24020864

Citations 6

Authors

Catherine M McGorrian

Sarah Lyster

Andrew Roy

Heloise Tarrant

Mary Codd

Peter Doran

Maria Fitzgibbon

Joseph Galvin

Niall G Mahon

Affiliations

Soon will be listed here.

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is a genetic condition, and relatives of affected persons may be at risk. Cardiac troponin biomarkers have previously been shown to be elevated in HCM. This study examines the new highly-sensitive cardiac troponin I (hsTnI) assay in a HCM screening population.

Methods: Nested case-control study of consecutive HCM sufferers and their relatives recruited from May 2010 to September 2011. After informed consent, participants provided venous blood samples and clinical and echocardiographic features were recorded. Associations between the natural log (ln) of the contemporary troponin I (cTnI) and hsTnI assays and markers of cardiac hypertrophy were examined. Multiple regression models were fitted to examine the predictive ability of hsTnI for borderline or definite HCM.

Results: Of 107 patients, 24 had borderline and 19 had definite changes of HCM. Both TnI assays showed significant, positive correlations with measures of cardiac muscle mass. After age and sex adjustment, the area under the receiver operator characteristic (AUROC) curve for the outcome of HCM was 0.78, 95% CI [0.65, 0.90], for ln(hsTnI), and 0.66, 95% CI [0.51, 0.82], for ln(cTnI) (p=0.11). Including the hsTnI assay in a multiple-adjusted "screening" model for HCM resulted in a non-significant improvement in both the AUROC and integrated discrimination index.

Conclusions: Both cTnI and hsTnI show a graded, positive association with measures of cardiac muscle mass in persons at risk of HCM. Further studies will be required to evaluate the utility of these assays in ECG- and symptom-based identification of HCM in at-risk families.

Citing Articles

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.

Sarwer K, Lashari S, Rafaqat N, Maher , Raheem A, Rehman M Egypt Heart J. 2024; 76(1):156.

PMID: 39645546 PMC: 11625047. DOI: 10.1186/s43044-024-00587-y.

Clinical findings using echocardiography and plasma cardiac troponin I and pathological findings in dogs with hypertrophic cardiomyopathy: A retrospective study.

Ando T, Izawa T, Nishida H, Akiyoshi H Open Vet J. 2023; 13(6):742-752.

PMID: 37545712 PMC: 10399649. DOI: 10.5455/OVJ.2023.v13.i6.9.

Circulating Biomarkers in Hypertrophic Cardiomyopathy.

Matthia E, Setteducato M, Elzeneini M, Vernace N, Salerno M, Kramer C J Am Heart Assoc. 2022; 11(23):e027618.

PMID: 36382968 PMC: 9851432. DOI: 10.1161/JAHA.122.027618.

Hypertrophic Cardiomyopathy: The Time-Synchronized Relationship between Ischemia and Left Ventricular Dysfunction Assessed by Highly Sensitive Troponin I and NT-proBNP.

Rajtar-Salwa R, Gebka A, Dziewierz A, Dimitrow P Dis Markers. 2019; 2019:6487152.

PMID: 31320942 PMC: 6610740. DOI: 10.1155/2019/6487152.

A One Health Approach to Hypertrophic Cardiomyopathy.

Ueda Y, Stern J Yale J Biol Med. 2017; 90(3):433-448.

PMID: 28955182 PMC: 5612186.

References

Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y . Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J. 2011; 75(4):919-26. DOI: 10.1253/circj.cj-10-0782. View

Basavarajaiah S, Wilson M, Whyte G, Shah A, Mckenna W, Sharma S . Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008; 51(10):1033-9. DOI: 10.1016/j.jacc.2007.10.055. View

Saunders J, Nambi V, de Lemos J, Chambless L, Virani S, Boerwinkle E . Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011; 123(13):1367-76. PMC: 3072024. DOI: 10.1161/CIRCULATIONAHA.110.005264. View

Cambronero F, Marin F, Roldan V, Hernandez-Romero D, Valdes M, Lip G . Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J. 2009; 30(2):139-51. DOI: 10.1093/eurheartj/ehn538. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of.... J Am Soc Echocardiogr. 2005; 18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005. View

Hlatky M, Greenland P, Arnett D, Ballantyne C, Criqui M, Elkind M . Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119(17):2408-16. PMC: 2956982. DOI: 10.1161/CIRCULATIONAHA.109.192278. View

Keren A, Syrris P, McKenna W . Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008; 5(3):158-68. DOI: 10.1038/ncpcardio1110. View

Wilson M, Basavarajaiah S, Whyte G, Cox S, Loosemore M, Sharma S . Efficacy of personal symptom and family history questionnaires when screening for inherited cardiac pathologies: the role of electrocardiography. Br J Sports Med. 2007; 42(3):207-11. DOI: 10.1136/bjsm.2007.039420. View

Maron B . Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287(10):1308-20. DOI: 10.1001/jama.287.10.1308. View

10.

Gottdiener J, Bednarz J, Devereux R, Gardin J, Klein A, Manning W . American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr. 2004; 17(10):1086-119. DOI: 10.1016/j.echo.2004.07.013. View

11.

Maron B, McKenna W, Danielson G, Kappenberger L, Kuhn H, Seidman C . American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the.... J Am Coll Cardiol. 2003; 42(9):1687-713. DOI: 10.1016/s0735-1097(03)00941-0. View

12.

Gersh B, Maron B, Bonow R, Dearani J, Fifer M, Link M . 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the.... J Am Coll Cardiol. 2011; 58(25):e212-60. DOI: 10.1016/j.jacc.2011.06.011. View

13.

Taniguchi R, Sato Y, Nishio Y, Kimura T, Kita T . Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels. 2006; 21(6):344-9. DOI: 10.1007/s00380-006-0909-1. View

14.

Sato Y, Taniguchi R, Nagai K, Makiyama T, Okada H, Yamada T . Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart. 2003; 89(6):659-60. PMC: 1767695. DOI: 10.1136/heart.89.6.659. View

15.

Desai M, Ommen S, McKenna W, Lever H, Elliott P . Imaging phenotype versus genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2011; 4(2):156-68. DOI: 10.1161/CIRCIMAGING.110.957936. View

16.

Apple F, Collinson P . Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2011; 58(1):54-61. DOI: 10.1373/clinchem.2011.165795. View

17.

Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Hoshikawa E . Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. Clin Cardiol. 2010; 33(2):E1-7. PMC: 6653149. DOI: 10.1002/clc.20622. View

18.

Forissier J, Charron P, Tezenas du Montcel S, Hagege A, Isnard R, Carrier L . Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. Eur Heart J. 2005; 26(18):1882-6. DOI: 10.1093/eurheartj/ehi276. View

19.

Spirito P, BELLONE P, Harris K, Bernabo P, Bruzzi P, Maron B . Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(24):1778-85. DOI: 10.1056/NEJM200006153422403. View

20.

Pencina M, DAgostino Sr R, DAgostino Jr R, Vasan R . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2007; 27(2):157-72. DOI: 10.1002/sim.2929. View